Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Metagenomi, Inc. due to alleged violations of federal securities laws related to misleading statements about its collaboration with Moderna, which has led to significant investor losses [3][4][5]. Group 1: Company Overview - Metagenomi, Inc. is described as a "genetic medicines company" that had a collaboration with Moderna, a leading Covid-19 vaccine company [4]. - The company completed its initial public offering on February 13, 2024, selling 6.25 million shares at $15 per share [5]. Group 2: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 between February 9, 2024, and September 26, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Metagenomi, with a deadline of November 25, 2024, for investors to seek the role of lead plaintiff [1][6]. Group 3: Allegations and Impact - The complaint alleges that Metagenomi and its executives made false or misleading statements regarding their collaboration agreement with Moderna [3]. - Following the announcement of the termination of the collaboration agreement on May 1, 2024, Metagenomi's stock price fell from $7.04 to $6.17 per share within a day, indicating a negative market reaction [5].

Core Viewpoint - A class action lawsuit has been filed against Metagenomi, Inc. for allegedly misleading statements made during its IPO, particularly regarding its collaboration with Moderna, which was terminated shortly after the IPO [1][3]. Company Overview - Metagenomi, Inc. conducted its IPO on February 12, 2024, selling approximately 6.25 million shares at $15 per share [2]. - The company positioned itself as a "genetic medicines company" with a longstanding relationship with Moderna, a leading Covid-19 vaccine company [3]. Recent Developments - On May 1, 2024, Metagenomi announced the termination of its collaboration with Moderna, leading to a significant drop in its share price from $7.04 to $6.17, a decline of $0.87 or 12.4% [2]. Legal Proceedings - Investors who acquired Metagenomi securities during the class period from February 9, 2024, to May 1, 2024, have until November 25, 2024, to apply to be appointed as lead plaintiff in the lawsuit [1].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Metagenomi, Inc. regarding a class action lawsuit related to the company's initial public offering and subsequent termination of its collaboration with Moderna [1][3]. Group 1: Company Overview - Metagenomi, Inc. is characterized as a "genetic medicines company" that had a significant partnership with Moderna, which was highlighted during its initial public offering [3]. - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [3]. Group 2: Allegations and Impact - The lawsuit arises from allegations that Metagenomi misled investors about its collaboration with Moderna, which was a critical aspect of its business model [3]. - Following the announcement of the termination of the collaboration on May 1, 2024, Metagenomi's stock price fell from $7.04 to $6.17 within a day, indicating a significant market reaction to the news [3]. Group 3: Legal Proceedings - The class action lawsuit is on behalf of shareholders who purchased stock during the IPO period from February 9 to 13, 2024 [2]. - Shareholders are encouraged to register for the class action by November 25, 2024, to potentially become lead plaintiffs and to receive updates on the case [4].

NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Metagenomi investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between Februa ...

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Metagenomi investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between ...

NEW YORK, Sept. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=105586&from=4 CLASS PERIOD: This lawsuit is on beh ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Metagenomi, Inc. stock related to its IPO conducted in February 2024, following the termination of a collaboration agreement with Moderna, which allegedly caused investor damages [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Metagenomi's IPO, where 6.25 million shares were sold at $15 each [5]. - The lawsuit claims that Metagenomi misrepresented its business relationship with Moderna, which was terminated less than three months after the IPO [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by November 25, 2024, to represent other class members [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

Group 1 - A class action lawsuit has been filed against Metagenomi, Inc. in the United States District Court for the Northern District of California on behalf of investors who purchased Metagenomi securities during the initial public offering period from February 9, 2024, to May 1, 2024 [1] - The complaint alleges that Metagenomi made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3] - The company presented itself as a "genetic medicines company" with a significant collaboration with Moderna, claiming a Strategic Collaboration and License Agreement established on October 29, 2021, which included multiple research programs [3]

SAN DIEGO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities who purchased stock pursuant to and/or traceable to Metagenomi Inc.'s (NASDAQ: MGX) registration statement for the initial public offering (IPO) held between February 9 and 13, 2024. Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. For more information, ...

Core Viewpoint - A class action lawsuit has been filed against Metagenomi, Inc. for alleged violations of federal securities laws related to misleading statements made during its IPO [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors who purchased Metagenomi's securities during its IPO on February 9, 2024, and encourages them to contact the firm before November 25, 2024 [2]. - The lawsuit claims that Metagenomi made false and misleading statements regarding its business relationship with Moderna, which was based on a Strategic Collaboration and License Agreement from October 29, 2021 [4]. Group 2: Impact on Investors - Following the announcement of the termination of the collaboration with Moderna, investors suffered damages as the truth about Metagenomi's misleading public statements was revealed [4].